Veru Inc. has provided an overview of its cardiometabolic drug development pipeline, focusing on treatments for obesity and atherosclerosis. The company is advancing a combination of enobosarm, an oral selective androgen receptor modulator (SARM), with a GLP-1 receptor agonist for weight loss maintenance in older patients. This combination aims to preserve muscle mass and enhance fat loss, addressing the significant lean mass reduction associated with current GLP-1 receptor agonist therapies. Phase 2 studies have shown positive results, with further clinical trials planned. Additionally, Veru is developing sabizabulin, an oral microtubule disruptor, for the treatment of inflammation in stable coronary artery disease. The scientific advisory board includes leading experts in endocrinology, metabolism, and cardiology. You can access the full presentation through the link below.